AJP - Renal Physiology, Vol 271, Issue 1 78-F86, Copyright © 1996 by American Physiological Society

ARTICLES

Differential regulation of kallikrein, kininogen, and kallikrein-binding protein in arterial hypertensive rats

C. Chao, P. Madeddu, C. Wang, Y. Liang, L. Chao and J. Chao
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston 29425, USA.

This study was designed to determine whether the kallikrein-kinin system exerts a protective action in hypertension induced by chronic inhibition of nitric oxide synthase. N omega-nitro-L-arginine methyl ester (L-NAME, 40 mg/100 ml water) was given orally to Sprague-Dawley rats, while controls received regular tap water. Hepatic kininogen mRNA levels in the L-NAME-treated group were 2.9- and 2.5-fold higher at 3 and 4 wk, respectively, compared with control rats, whereas kallikrein-binding protein (KBP) mRNA levels were 82% and 45% of the values found in control rats at 3 and 4 wk, respectively. There was no significant change in hepatic alpha 1-antitrypsin mRNA levels under the same conditions. At 3 and 4 wk post L-NAME treatment, renal kallikrein mRNA levels were 2.5- and 3.4-fold higher than in controls, whereas renal beta-actin mRNA levels were similar between groups. Changes in the transcript levels of renal kallikrein, kininogen, and KBP were consistent with their protein levels. Immunoreactive total kininogen and low-Mr kininogen levels in sera and tissue kallikrein levels in kidney were significantly higher in the L-NAME-treated group, whereas KBP levels in the circulation were lower compared with controls. Systolic blood pressure was increased by 58 +/- 4 mmHg after 4 wk of L-NAME treatment. This effect was enhanced in rats given L-NAME in combination with HOE-140, a bradykinin B2-receptor antagonist, at the dose of 100 micrograms/day ip (79 +/- 5 vs. 58 +/- 4 mmHg, P < 0.05). This difference was confirmed by direct measurement of mean blood pressure (MBP). An intra-arterial bolus injection of 200 ng bradykinin significantly decreased MBP of L-NAME-treated rats, and this effect was blunted in the group treated with the bradykinin antagonist (-29 +/- 3 vs. -9 +/- 2 mmHg, P < 0.01). These results suggest that enhanced kallikrein and kininogen synthesis may have a protective role against the cardiovascular effects induced by chronic inhibition of nitric oxide synthesis.

This article has been cited by other articles:

				S. S. El-Dahr, K. Aboudehen, and S. Dipp Bradykinin B2 receptor null mice harboring a Ser23-to-Ala substitution in the p53 gene are protected from renal dysgenesis Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1404 - F1413. [Abstract] [Full Text] [PDF]

				F. Schwartz, A. Duka, E. Triantafyllidi, C. Johns, I. Duka, J. Cui, and H. Gavras Serial analysis of gene expression in mouse kidney following angiotensin II administration Physiol Genomics, December 16, 2003; 16(1): 90 - 98. [Abstract] [Full Text] [PDF]

				A. Stadnicki, J. Chao, I. Stadnicka, E. Van Tol, K.-F. Lin, F. Li, R. B. Sartor, and R. W. Colman Localization and secretion of tissue kallikrein in peptidoglycan-induced enterocolitis in Lewis rats Am J Physiol Gastrointest Liver Physiol, October 1, 1998; 275(4): G854 - G861. [Abstract] [Full Text] [PDF]

				C. Wang, P. Ford, C. Chao, L. Chao, and J. Chao Effect of cyclosporin A on the expression of tissue kallikrein, kininogen, and bradykinin receptor in rat Am J Physiol Renal Physiol, November 1, 1997; 273(5): F783 - F789. [Abstract] [Full Text] [PDF]